Prostate Cancer Clinical Trials

Showing 121-140 of 2,150 trials

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

NCT05751941

This study is designed to test the hypothesis that using Sipuleucel-T (Provenge) in combination with new hormonal agents (NHA) (abiraterone, enzalutamide, apalutamide) for the treatment of participants with asymptomatic metastatic castration resistant prostate cancer (mCRPC) and no visceral metastases would enhance the activation of antigen presenting cells (APC) by sipuleucel-T.

Prostate CancerMetastatic Prostate Cancer

H. Lee Moffitt Cancer Center and Research Institute26 participantsStarted Feb 2023

Tampa, Florida, United States • Columbus, Ohio, United States

Active Not RecruitingPhase 2

A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer

NCT04190446

This phase II trial studies the side effects of radiation therapy (hypofractionated proton beam therapy or IMRT) for the treatment of prostate cancer that has come back (recurrent) or that has spread to a limited number of sites (oligometastatic) following primary localized treatment. Hypofractionated proton beam radiation therapy delivers smaller doses of radiation therapy over time and may kill more tumor cells and have fewer side effects. IMRT uses high energy x-rays to kill tumor cells and shrink tumors. This trial is being done to find out if a shorter course of radiation therapy is better with fewer side effects for patients with recurrent prostate cancer.

Metastatic Prostate AdenocarcinomaOligometastatic Prostate CarcinomaProstate Adenocarcinoma+2 more

Mayo Clinic84 participantsStarted Jan 2020

Rochester, Minnesota, United States

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer

Related Searches

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Leveraging EA8191 to Assess AI-Augmented EHR Abstraction

PROCARE - PROstate Cancer Real World Evidence Registry

Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial

CARE Tool Study Aim 3

Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy

PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With Unfavorable Intermediate Risk Prostate Cancer

Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

MRI Guided SBRT for Localized Prostate Cancer